Representatives Seal

Fiscal Note

S.C.R. 5

2026 General Session

Concurrent Resolution Directing PEHP Regarding Pain Medication

by Weiler, Todd

Senate Seal
General, Income Tax, and Uniform School FundsJR4-4-101
OngoingOne-timeTotal
Net GF/ITF/USF (rev.-exp.) $(338,400) $0 $(338,400)


State GovernmentUCA 36-12-13(2)(c)
Revenues FY2026 FY2027 FY2028
Total Revenues $0 $0 $0

Enactment of this legislation likely will not materially impact state revenue.


Expenditures FY2026 FY2027 FY2028
Transportation Fund $0 $50,900 $50,900
Other Financing Sources $0 $42,000 $42,000
Federal Funds $0 $111,800 $111,800
Dedicated Credits Revenue $0 $36,400 $36,400
General Fund $0 $313,900 $313,900
Income Tax Fund $0 $24,500 $24,500
Total Expenditures $0 $579,500 $579,500

Enactment of this legislation could cost the Public Employees Health Program (PEHP) $579,500 ongoing beginning in FY 2027, with state agencies charged $313,900 from the General Fund, $24,500 from the Income Tax Fund, and $241,100 from other sources, for medication costs required by the legislation.


FY2026 FY2027 FY2028
Net All Funds (rev-exp) $0 $(579,500) $(579,500)
Local GovernmentUCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

Individuals & BusinessesUCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.

Regulatory ImpactUCA 36-12-13(2)(d)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

Performance EvaluationJR1-4-601

This bill does not create a new program or significantly expand an existing program.